Pregnant women and infants are at risk should they contract mpox but there are no approved vaccines for this population.

Bavarian Nordic gets $63 million US government order for small pox, mpox vaccine September 24, 2024 Future of Healthcategory Bavarian says mpox vaccine approved by EU regulator for adolescents ...

In September, after facing criticism on moving too slowly on vaccines, the World Health Organization cleared Bavarian Nordic's vaccine for mpox and said it was considering LC16, made by Japan's KM ...

The World Health Organisation said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...

A clinical trial by the US National Institutes of Health (NIH) has shown that Bavarian Nordic’s mpox vaccine induced an antibody response in adolescents equivalent to that of adults. The interim ...

An initial 899,000 vaccine doses have been allocated for 9 countries across Africa that have been hit hard by the current mpox surge, the WHO and other health organisations said on Wednesday.

Results from this study could support an extension of the current approval of MVA-BN to include children from 2 years of age ...

While Bavarian Nordic’s vaccine Jynneos is approved in several countries to prevent mpox and smallpox infections in adults, there has been a lack of data to support its approval in adolescents.